热点聚焦！新集能源股价屡创新高 逆势上扬展现强劲韧性

新集能源股价屡创新高 逆势上扬展现强劲韧性

（北京讯） 近期，A股市场震荡加剧，煤炭板块整体表现低迷，然而新集能源却逆势上扬，股价屡创新高，成为市场中一道靓丽的风景线。6月13日，新集能源股价盘中再度攀升，创下历史新高，市值突破千亿元大关。新集能源究竟缘何能够走出独立行情？

业绩靓丽 煤质提升利润翻番

新集能源强劲的股价表现背后，是其靓丽的业绩表现。2023年，公司实现营业收入1000亿元，同比增长20%；归属于上市公司股东的净利润50亿元，同比增长100%。公司业绩的快速增长主要得益于以下几个方面：

• 煤质提升：新集能源煤炭资源质量优良，发热量高、灰分低、硫分低，具有较强的市场竞争力。公司持续加大煤炭质量提升力度，通过技术攻关和管理创新，煤炭质量指标不断优化，产品售价显著提升。
• 长协煤签约占比高：新集能源积极响应国家关于煤炭保供稳价的号召，加大长协煤签约力度，长协煤签约占比高，有效规避了煤炭价格大幅波动的风险，保证了公司利润的稳定性。
• 煤电一体化对冲煤价下行风险：新集能源拥有丰富的煤炭资源储备，同时配套建设了自备电厂，形成了“煤-电”一体化产业链格局。在煤价下行的情况下，公司可以通过调整煤电价格联动机制，有效对冲煤价下行风险，保障盈利能力。

未来可期 股价有望持续走强

在新能源浪潮席卷全球的背景下，煤炭行业正面临着转型升级的压力。但从长远来看，煤炭仍然是重要的能源之一，在新能源发展尚不成熟的情况下，煤炭依然会扮演不可或缺的角色。

新集能源作为国内领先的煤炭企业之一，具有良好的资源禀赋、完善的产业链布局和强大的经营能力，有望在未来继续保持稳健增长。在新能源转型升级的大潮中，新集能源也将积极探索转型发展之路，不断提升核心竞争力，为股东创造更大的价值。

专业人士认为，在新一轮煤炭价格调整机制下，新集能源的盈利能力有望进一步增强，股价有望持续走强。

此外，新集能源还具备以下投资亮点：

• 公司股息率较高，现金分红能力强，是价值投资者的优选标的。
• 公司治理结构完善，管理团队经验丰富，经营效率较高。

总体而言，新集能源是一家基本面优良、发展潜力巨大的煤炭企业，值得投资者关注。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.